Boston Scientific Corporation (NYSE:BSX) is one of the most promising future stocks to buy right now. Stifel cut the price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $75 on June 25 and reaffirmed a Buy rating on the shares. The rating update came after the firm hosted five deep left atrial appendage closure physician conversations to talk about why Watchman growth has slowed. It added that the doctors highlighted multiple factors, including negative reactions to multiple recent datasets, OR capacity constraints, and site-of-care saturation.
In a separate development, BofA cut the price target on Boston Scientific Corporation to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, and Barclays wants to take a more conservative view on 2027 medtech company estimates, given valuations are already reflecting utilization risk. It further told investors that the firm is lowering 2027 estimates across its larger-cap coverage where there’s exposure to utilization and inflation.
Boston Scientific Corporation manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
